Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study

Keyphrases

• Previously Treated 100%
• Phase II Study 100%
• Anthracyclines 100%
• Metastatic Breast Cancer 100%
• Taxanes 100%
• Vinorelbine 100%
• Tegafur-uracil 100%
• AEMPS 25%
• Chemotherapy 25%
• Breast Cancer 25%
• Bone Marrow 25%
• Renal Function 25%
• Intention-to-treat 25%
• Median Time 25%
• Liver Function 25%
• Overall Response Rate 25%
• Safety Profile 25%
• Trial Registration 25%
• Metastatic Disease 25%
• Median Overall Survival 25%
• Chemotherapy Regimen 25%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 25%
• Asthenia 25%
• Neutropenia 25%
• Severe Toxicity 25%
• Efficacy Analysis 25%
• Measurable Disease 25%
• Time to Progression 25%
• Prior Chemotherapy 25%
• Efficacy Profile 25%
• Performance Status 2 25%
• Toxicity Analysis 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Anthracycline 100%
• Metastatic Breast Cancer 100%
• Vinorelbine 100%
• UFT 100%
• Taxane 100%
• Chemotherapy 25%
• Disease 25%
• Breast Cancer 25%
• Overall Survival 25%
• Metastasis 25%
• Chemotherapy Regimens 25%
• Asthenia 25%
• Neutropenia 25%
• Patient History of Chemotherapy 25%